Polymorbid patient with hypertension and cognitive impairment. Modern principles of treatment
Ostroumova Olga Dmitrievna - Doctor of Medical Sciences, Professor, Head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Federal State Budgetary Educational Institution of Higher Professional Education RMANPO of the Ministry of Health of the Russian Federation
Announcement:
We present to your attention the speech of the head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi of the Federal State Budgetary Educational Institution of Higher Professional Education RMANPO of the Ministry of Health of the Russian Federation, Olga Dmitrievna Ostroumova - her report is devoted to the comprehensive management of patients with arterial hypertension and cognitive impairment.
Thanks to this video you will learn:
- Why are cognitive impairments not just “poor memory”, but the earliest sign of brain damage in hypertension, according to European and Russian clinical guidelines?
- How common are they? In 75% or more of patients with hypertension - even in middle age!
- Why is cognitive impairment not only a risk for dementia but also a major reason for poor adherence to treatment?
- How does every 5 points on the KSHOPS scale reduce survival by 34%?
The diagnostics are discussed in detail during a doctor's appointment:
- In what clinical situations should which neuropsychological tests and scales be used? Mini-Cog (5 minutes) and MoCA (10-15 minutes)?
- Why is the Symbol Substitution Test (DST) one of the most sensitive markers of attention and information processing impairment?
- How to assess subjective cognitive complaints in normal tests?
Basic therapy is not only hypertension:
- Control of blood pressure to target values (120–129/70–79 mmHg);
- Correction of dyslipidemia, diabetes, atrial fibrillation;
- The MIND diet reduces the risk of Alzheimer's disease even with moderate adherence.
Key takeaway: Neuroprotection is not an option, but a necessity!
Based on the MEMO study, the high efficacy of Mexidol in patients with chronic cerebral ischemia and hypertension has been proven.
Watch the report to:
- Learn to identify cognitive impairment at the preclinical stage;
- Understand how to build a comprehensive strategy for managing a polymorbid patient;
- Find out why Mexidol is an evidence-based choice.
The video is a must-see for therapists, cardiologists, neurologists and general practitioners.